Key facts
- Indomo’s last known valuation is $78.5M (May 2025).
- It has raised $42.2M; the latest was Early Stage VC ($25.0M) in May 2025.
- Notable investors include Mana Ventures, Gaingels, Evolution VC Partners, Polaris Partners, Foresite Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Indomo
- ·The full record, as it builds
Funding rounds
No funding rounds for Indomo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Indomo
Developer of acne care therapeutics intended to offer device-enabled innovations for acne care. The company offers an acne drug paired with a novel intradermal self-injection device for the resolution of moderate to severe acne lesions, allowing patients to access intralesional acne injections whenever and wherever they need them.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 7
- Website
- indomotx.com/
- Ownership
- Privately Held (backing)
Indomo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Indomo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Indomo in its N-PORT filings yet. We sweep new filings monthly.